CYP3A4 and B-cell chronic lymphocytic leukemia: We aim to address the variability in efficacy and safety among CLL patients undergoing ibrutinib treatment by quantifying plasma ibrutinib levels and identifying CYP3A polymorphisms that impair enzyme functionality.